WASHINGTON, DC 20549


                                 SCHEDULE 14D-9

          Solicitation/Recommendation Statement Under Section 14(d)(4)
                     of the Securities Exchange Act of 1934
                               (Amendment No. 11)


                                 RIBAPHARM INC.
                            (Name of Subject Company)

                                 RIBAPHARM INC.
                      (Name of Person(s) Filing Statement)

                     Common Stock, par value $.01 per share
                         (Title of Class of Securities)

                      (CUSIP Number of Class of Securities)


                                Daniel J. Paracka
                              Chairman of the Board
                                 Ribapharm Inc.
                               3300 Hyland Avenue
                          Costa Mesa, California 92626
                                 (714) 427-6236

                                 With copies to:

                             Esteban A. Ferrer, Esq.
                      Paul, Hastings, Janofsky & Walker LLP
                            1055 Washington Boulevard
                           Stamford, Connecticut 06901
                                 (203) 961-7400
   (Name, Address and Telephone Number of Person Authorized to Receive Notices
         and Communications on Behalf of the Person(s) Filing Statement)

|_| Check the box if the filing relates solely to preliminary communications
    made before the commencement of a tender offer.

        This Amendment No. 11 amends and supplements the Schedule 14D-9 filed
with the Securities and Exchange Commission (the "SEC") on June 23, 2003 and as
subsequently amended (the "Schedule 14D-9") by Ribapharm Inc., a Delaware
corporation ("Ribapharm" or the "Company"), relating to the tender offer by Rx
Acquisition Corporation, a Delaware corporation ("Purchaser"), and a
wholly-owned subsidiary of ICN Pharmaceuticals, Inc., a Delaware corporation
("ICN"), to purchase all of the outstanding shares of Ribapharm's common stock,
par value $.01 per share, which are not currently owned by ICN and its
subsidiaries (the "Publicly Held Shares"), at a purchase price of $ 6.25 per
share (the "Offer Price"), net to the seller in cash, without interest thereon,
upon the terms and subject to the conditions set forth in Purchaser's Offer to
Purchase, dated June 10, 2003 (the "Offer to Purchase"), as subsequently
amended, and in the related Letter of Transmittal (which together with the Offer
to Purchase and any amendments or supplements thereto collectively constitute
the "Offer"). The Offer is disclosed on a Tender Offer Statement and Rule 13e-3
Transaction Statement filed under cover of Schedule TO with the SEC on June 10,
2003 by ICN and as subsequently amended (the "Schedule TO"). Capitalized terms
used herein and not otherwise defined have the meanings ascribed to them in the
Schedule 14D-9.

Item 9.        Exhibits.

        Item 9 is hereby amended and supplemented as follows: On August 5, 2003,
the Company filed with the SEC Amendment No. 10 to its "Solicitation/
Recommendation Statement" on Schedule 14D-9 that omitted as an exhibit thereto
the Agreement, dated August 4, 2003, by and among Ribapharm Inc., ICN
Pharmaceuticals, Inc. and Rx Acquisition Corporation. The Agreement is attached
hereto as Exhibit (e)(51) and is incorporated herein by reference.

       (e)(51) Agreement, dated August 4, 2003, by and among Ribapharm Inc., ICN
               Pharmaceuticals, Inc. and Rx Acquisition Corporation.


        After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

                                                 RIBAPHARM INC.

                                                 By:  /s/ Daniel J. Paracka
                                                 Name:  Daniel J. Paracka
                                                 Title: Chairman of the Board of
Dated:  August 11, 2003